These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8991040)

  • 81. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Adams HP; Woolson RF; Clarke WR; Davis PH; Bendixen BH; Love BB; Wasek PA; Grimsman KJ
    Control Clin Trials; 1997 Aug; 18(4):358-77. PubMed ID: 9257073
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Danaparoid reduces transplant-related mortality in stem cell transplantation for children.
    Kato K; Sakaguchi H; Muramatsu H; Sekiya Y; Kawashima N; Narita A; Doisaki S; Watanabe N; Yoshida N; Matsumoto K
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29239087
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Use of a low molecular weight preparation of heparin--ORG 10172 (Lomoparan) in the critically ill.
    John G; Shehabi Y; Mudaliar Y
    Anaesth Intensive Care; 1991 Nov; 19(4):588-91. PubMed ID: 1721505
    [No Abstract]   [Full Text] [Related]  

  • 84. Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST).
    Wilterdink JL; Bendixen B; Adams HP; Woolson RF; Clarke WR; Hansen MD
    Stroke; 2001 Dec; 32(12):2836-40. PubMed ID: 11739983
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Adams HP; Davis PH; Leira EC; Chang KC; Bendixen BH; Clarke WR; Woolson RF; Hansen MD
    Neurology; 1999 Jul; 53(1):126-31. PubMed ID: 10408548
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria.
    Goldstein LB; Jones MR; Matchar DB; Edwards LJ; Hoff J; Chilukuri V; Armstrong SB; Horner RD
    Stroke; 2001 May; 32(5):1091-8. PubMed ID: 11340215
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST).
    Hassaballa H; Gorelick PB; West CP; Hansen MD; Adams HP
    Neurology; 2001 Aug; 57(4):691-7. PubMed ID: 11524481
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Differences between anterior and posterior circulation stroke in TOAST.
    Libman RB; Kwiatkowski TG; Hansen MD; Clarke WR; Woolson RF; Adams HP
    Cerebrovasc Dis; 2001; 11(4):311-6. PubMed ID: 11385210
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Heparinoids with low anticoagulant potency attenuate postischemic endothelial cell dysfunction.
    Sternbergh WC; Sobel M; Makhoul RG
    J Vasc Surg; 1995 Mar; 21(3):477-83. PubMed ID: 7877230
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Circadian variation in ischemic stroke subtypes.
    Chaturvedi S; Adams HP; Woolson RF
    Stroke; 1999 Sep; 30(9):1792-5. PubMed ID: 10471425
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Heparin and extracorporeal circulation].
    THIES HA
    Thromb Diath Haemorrh; 1961; 5(Suppl)():99-130. PubMed ID: 13920693
    [No Abstract]   [Full Text] [Related]  

  • 92. The use of ACD blood for extracorporeal circulation.
    Maloney JV
    Transfusion; 1966; 6(4):369-71. PubMed ID: 5965706
    [No Abstract]   [Full Text] [Related]  

  • 93. [Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].
    Christin F; Theissen-Laval O; Loeb JP
    Ann Fr Anesth Reanim; 1998; 17(1):82-3. PubMed ID: 9750692
    [No Abstract]   [Full Text] [Related]  

  • 94. [Danaparoid sodium].
    Kitazawa Y
    Rinsho Byori; 2011 Feb; Suppl 147():164-6. PubMed ID: 21761765
    [No Abstract]   [Full Text] [Related]  

  • 95. [Use of Orgaran for extracorporeal circulation in a patient allergic to heparin].
    Bretelle C; Leude E; Quilici J; Vaillant A
    Presse Med; 1996 Nov; 25(37):1846-7. PubMed ID: 8991040
    [No Abstract]   [Full Text] [Related]  

  • 96. [Value of orgaran in hemodialysis during heparin-induced thrombopenia].
    Lamriben L; Tiberghien F; Delacour JL; Floriot C; Wagschal G; Daoudal P; Ory JP
    Presse Med; 1996 Sep; 25(28):1303. PubMed ID: 8949796
    [No Abstract]   [Full Text] [Related]  

  • 97. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.
    Tardy/Poncet B; Mahul P; Beraud AM; Favre JP; Tardy B; Guyotat D
    Br J Haematol; 1995 Aug; 90(4):969-70. PubMed ID: 7669684
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.